Gara Jalqabaatti › Non-Hodgkin Lymphoma › Tennessee › Nashville
Qorannoo klinikaalii Non-Hodgkin Lymphoma Nashville, TN keessatti
Qorannoo 21 Non-Hodgkin Lymphoma f Nashville fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Namoota walitti qabaa jiraSadarkaa 1/2
- SCRI Oncology Partners ( Site 0100), Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Namoota walitti qabaa jiraSadarkaa 1
- SCRI Oncology Partners, Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Namoota walitti qabaa jiraSadarkaa 2
- Research Site, Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Namoota walitti qabaa jiraSadarkaa 2
- Tennessee Oncology, Nashville
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Namoota walitti qabaa jiraSadarkaa 1
- SCRI Oncology Partners, Nashville
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Franklin · Miili 17 fagaatti
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Namoota walitti qabaa jiraSadarkaa 3
- Sarah Cannon Research Institute SCRI, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Namoota walitti qabaa jiraSadarkaa 1/2
- TriStar BMT, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Namoota walitti qabaa jiraSadarkaa 3
- SCRI Oncology Partners, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
Namoota walitti qabaa jiraSadarkaa 2
- SCRI Oncology Partners, Nashville
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Vanderbilt University, Nashville
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Namoota walitti qabaa jiraSadarkaa 4
- Tennessee Oncology, Nashville
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 4
- Tennessee Oncology, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Nashville
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- SCRI Oncology Partners, Nashville
Qorannoo Non-Hodgkin Lymphoma magaalota biroo keessatti
- New York City, NYQorannoo 31
- Houston, TXQorannoo 31
- Boston, MAQorannoo 26
- Philadelphia, PAQorannoo 20
- Baldwin Park, CAQorannoo 19
- Washington, DCQorannoo 18
- Chicago, ILQorannoo 18
- Atlanta, GAQorannoo 18
- Milwaukee, WIQorannoo 18
- Columbus, OHQorannoo 18
- Dallas, TXQorannoo 17
- Seattle, WAQorannoo 16
Qorannoo biroo Nashville keessatti
- Kansara Qara'a Non-Small CellQorannoo 97
- Saree OljooQorannoo 81
- Kansara MetastatikiiQorannoo 70
- Kansarii ColorectalQorannoo 69
- Saree (Gosoota Hunda)Qorannoo 65
- Kansarii OvariiQorannoo 49
- Kansarii ProstateQorannoo 43
- Dhibee QaraQorannoo 40
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 39
- Kansarii PancreasQorannoo 39
- Kansa EndometiriyaaliiQorannoo 38
- MelanomaQorannoo 33
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.